Anita Sharma1, Arvind Madaan. 1. Department of Pediatrics, Pt. B.D. Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India. dr_anitassharma@sifymail.com
Abstract
OBJECTIVE: To see the additional benefit of combined frequent nebulization with salbutamol and ipratropium bromide in acute attack of asthma with moderate severity. METHODS:Fifty asthmatic children in the age range of 6-14 years were divided into two equal groups. Group I children were nebulized with three doses of Salbutamol alone (0.03 ml/kg/dose) and Group II children were given combined nebulization of Salbutamol (dose as in group I) and Ipratropium bromide (250 microgm/dose for three doses) at 20 minutes interval. Children were observed at 15, 30, 60, 120, 180 and 240 minutes interval. RESULTS: A significant improvement in % of PEFR starting at 30 minutes and lasting the entire study period of 4 hours was noted in both the groups. However on analysis of varience the results were better in group II. CONCLUSION: Frequent combined nebulization with Salbutamol and Ipratropium bromide is beneficial in acute asthma of moderate severity.
RCT Entities:
OBJECTIVE: To see the additional benefit of combined frequent nebulization with salbutamol and ipratropium bromide in acute attack of asthma with moderate severity. METHODS: Fifty asthmatic children in the age range of 6-14 years were divided into two equal groups. Group I children were nebulized with three doses of Salbutamol alone (0.03 ml/kg/dose) and Group II children were given combined nebulization of Salbutamol (dose as in group I) and Ipratropium bromide (250 microgm/dose for three doses) at 20 minutes interval. Children were observed at 15, 30, 60, 120, 180 and 240 minutes interval. RESULTS: A significant improvement in % of PEFR starting at 30 minutes and lasting the entire study period of 4 hours was noted in both the groups. However on analysis of varience the results were better in group II. CONCLUSION: Frequent combined nebulization with Salbutamol and Ipratropium bromide is beneficial in acute asthma of moderate severity.